- Company to highlight the '201' trial at
multiple regional seminars for physicians -
- Up to 61% of clinical sites actively
screening patients by close of 2Q23 -
BOSTON and ATLANTA, June 21,
2023 /PRNewswire/ -- Inhibikase Therapeutics,
Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage
pharmaceutical company developing protein kinase inhibitor
therapeutics to modify the course of Parkinson's disease ("PD"),
Parkinson's-related disorders and other diseases of the Abelson
Tyrosine Kinases, today announced a physician and patient awareness
campaign for its Phase 2 '201' program evaluating IkT-148009 as a
potentially disease-modifying treatment of Parkinson's disease.
Dr. Milton Werner, President
& CEO of Inhibikase Therapeutics will present to community
neurologists and movement disorder specialists at multiple regional
seminars where the Company has activated clinical trial sites. The
first two seminars will take place at the Westin Southfield in
Southfield, Michigan on
June 26 and at the Le Meridién
Dallas, the Stoneleigh, in
Dallas, Texas on July 11.
"Since we re-initiated the '201' trial, we have worked
diligently to reactivate and retrain clinical trial sites and
anticipate having up to 22 of 35 selected sites open for screening
by the end of the second quarter. Our clinical team is working
closely with each site to further improve patient screening
logistics as well as candidate identification," commented Dr.
Werner. "In addition, we are initiating an awareness campaign to
community neurologists and movement disorder specialists by hosting
regional medical seminars about IkT-148009 and its potential as a
transformative treatment for Parkinson's disease. Further, we plan
to launch a dedicated online patient portal (www.the201trial.com)
in the second quarter to provide patients a better understanding of
the trial and how to be evaluated for participation. Taken
together, we believe that these activities, in conjunction with the
significant enhancements we have made to the trial itself, will
allow us to enhance enrollment of the '201' trial."
Additional information about the trial is available at
www.clinicaltrials.gov using the identifier NCT05424276 and at
www.inhibikase.com/patient-resources.
About Inhibikase
(www.inhibikase.com)
Inhibikase Therapeutics,
Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company
developing therapeutics for Parkinson's disease and related
disorders. Inhibikase's multi-therapeutic pipeline has a primary
focus on neurodegeneration and its lead program IkT-148009, an
Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of
Parkinson's disease inside and outside the brain as well as other
diseases that arise from Ableson Tyrosine Kinases. Its
multi-therapeutic pipeline is pursuing Parkinson's-related
disorders of the brain and GI tract, orphan indications related to
Parkinson's disease such as Multiple System Atrophy, and drug
delivery technologies for kinase inhibitors such as IkT-001Pro, a
prodrug of the anticancer agent imatinib mesylate that the Company
believes will provide a better patient experience with fewer
on-dosing side-effects. The Company's RAMP™ medicinal chemistry
program has identified a number of follow-on compounds to
IkT-148009 to be potentially applied to other cognitive and motor
function diseases of the brain. Inhibikase is headquartered in
Atlanta, Georgia with an office in
Lexington, Massachusetts.
Social Media Disclaimer
Investors and others should
note that we announce material financial information to our
investors using our investor relations website, press releases, SEC
filings and public conference calls and webcasts. The Company
intends to also
use Twitter, Facebook, LinkedIn and YouTube as
a means of disclosing information about the Company, its services
and other matters and for complying with its disclosure obligations
under Regulation FD.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
terminology such as "believes," "expects," "may," "will," "should,"
"anticipates," "plans," or similar expressions or the negative of
these terms and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based on Inhibikase's current expectations and assumptions. Such
statements are subject to certain risks and uncertainties, which
could cause Inhibikase's actual results to differ materially from
those anticipated by the forward-looking statements, including our
ability to successfully conduct clinical trials, that results in
our animal studies may not be replicated in humans and our ability
to maintain our Nasdaq listing. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include factors that are delineated in
our periodic reports on Form 10-K and Form 10-Q that we file with
the U.S. Securities and Exchange Commission. Any forward-looking
statement in this release speaks only as of the date of this
release. Inhibikase undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by any applicable securities laws.
Contacts:
Company Contact:
Milton H.
Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex
Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-initiates-medical-and-patient-awareness-campaign-for-its-phase-2-201-trial-evaluating-ikt-148009-in-parkinsons-disease-301856071.html
SOURCE Inhibikase Therapeutics, Inc.